Article

Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancer

2021-12-07

Abstract excerpt

Triple-negative breast cancer (TNBC) is characterized by poor prognosis and aggressive growth, with limited therapeutic options for many patients. Here, we use two syngeneic mouse TNBC models, 4T1 and E0771, to investigate the chemo-immunogenic potential of cyclophosphamide and the mechanistic contributions of cyclophosphamide-activated type-I interferon (IFN) signaling to therapeutic activity. Chemically-activate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c3fe92a7-1536-5721-93d0-b8409177b951
DOI: 10.1101/2021.12.05.471293

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancerDOI 10.1101/2021.12.05.471293Read

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersSemantic proximity Read

A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapiesSemantic proximity Read

Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancerSemantic proximity Read

Combinatorial Immunotherapies Overcome MYC-Driven Immune EvasionSemantic proximity Read

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapySemantic proximity Read

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.Semantic proximity Read

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunitySemantic proximity Read

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingSemantic proximity Read

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity Read

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in miceSemantic proximity Read

MYC promotes immune-suppression in TNBC via inhibition of IFN signalingSemantic proximity Read

Advanced HCC precision modeling reveals divergent responses to combinatorial immunotherapySemantic proximity Read